Targeting autoreactive B cells using ADAMTS13-based chimeric auto-antigen receptors (CAARs) T cells for the treatment of immune thrombotic thrombocytopenic purpura (iTTP)

June 25, 2024 | Vijay Bhoj, M.D., Ph.D.; University of Pennsylvania; Philadelphia, PA, U.S.

RSS
135678910Last